First-line treatment of Hodgkin's lymphoma.
Substantial clinical progress over the last decades has made Hodgkin's lymphoma (HL) into one of the most curable human cancers in adults. About 80% of patients in all stages and of all histological subtypes experience long-term disease-free survival. Modern treatment strategies aim to improve chemotherapy and radiotherapy, while minimizing therapy-related toxicities. Ongoing trials investigate a reduction of chemotherapy doses or cycles and the application of lower-radiation doses and smaller radiation field sizes. For patients with a specific high-risk profile, novel approaches with more intense drug combinations are currently being investigated in clinical trials. Here, we review recent approaches in the first-line treatment of early-favorable, early-unfavorable, and advanced-stage HL.
Klimm
Beate
B
First Department of Internal Medicine, University Hospital Cologne, Herderstr. 52, 50931 Cologne, Germany. beate.klimm@biometrie.uni-koeln.de
Engert
Andreas
A
Diehl
Volker
V
D000293:Adolescent; D000328:Adult; D000368:Aged; D000465:Algorithms; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D019090:Case Management; D003131:Combined Modality Therapy; D005260:Female; D006689:Hodgkin Disease / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D007247:Infertility, Female / Q000209:etiology / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009367:Neoplasm Staging; D011878:Radiotherapy / Q000379:methods; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D016019:Survival Analysis; D016896:Treatment Outcome